Adaptive Biotechnologies Corporation (ADPT) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ADPT Revenue Growth
Revenue Breakdown (FY 2021)
ADPT's revenue distribution by segment and geography for fiscal year 2021
By Product/Segment
ADPT Revenue Analysis (2017–2025)
As of May 8, 2026, Adaptive Biotechnologies Corporation (ADPT) generated trailing twelve-month (TTM) revenue of $295.4 million, reflecting explosive growth of +35.1% year-over-year. The most recent quarter (Q1 2026) recorded $70.9 million in revenue, down 1.1% sequentially.
Looking at the longer-term picture, ADPT's 5-year compound annual growth rate (CAGR) stands at +23.0%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $277.0 million in 2025, representing a new all-time high.
Revenue diversification analysis shows ADPT's business is primarily driven by Sequencing Revenue (51%), Development Support Revenue (42%), and Development Revenue Regulatory Milestones (6%). With over half of revenue concentrated in Sequencing Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NTRA (+35.9% YoY), EXAS (+17.7% YoY), and PACB (+3.9% YoY), ADPT has underperformed the peer group in terms of revenue growth. Compare ADPT vs NTRA →
ADPT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ADPTCurrent | $295M | +35.1% | +23.0% | -20.6% | |
 NTRA | $2.3B | +35.9% | +42.6% | -13.4% | |
 EXAS | $3.2B | +17.7% | +16.8% | -6.4% | |
 PACB | $160M | +3.9% | +15.2% | -348.5% | |
 TWST | $377M | +17.8% | +33.1% | -36.2% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% |
ADPT Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $277.0M | +54.8% | $205.6M | 74.2% | $-57,123,000 | -20.6% |
| 2024 | $179.0M | +5.1% | $106.9M | 59.7% | $-162,549,000 | -90.8% |
| 2023 | $170.3M | -8.1% | $94.7M | 55.6% | $-227,035,000 | -133.3% |
| 2022 | $185.3M | +20.1% | $127.4M | 68.7% | $-200,186,000 | -108.0% |
| 2021 | $154.3M | +56.9% | $105.0M | 68.1% | $-208,966,000 | -135.4% |
| 2020 | $98.4M | +15.6% | $75.9M | 77.1% | $-152,817,000 | -155.3% |
| 2019 | $85.1M | +52.8% | $62.8M | 73.8% | $-78,391,000 | -92.1% |
| 2018 | $55.7M | +44.8% | $36.0M | 64.7% | $-49,756,000 | -89.4% |
| 2017 | $38.4M | - | $22.8M | 59.2% | $-44,475,000 | -115.7% |
See ADPT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ADPT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ADPT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonADPT — Frequently Asked Questions
Quick answers to the most common questions about buying ADPT stock.
Is ADPT's revenue growth accelerating or slowing?
ADPT revenue is accelerating at +35.1% year-over-year, exceeding the 5-year CAGR of +23.0%. TTM revenue reached $295M. Growth momentum has increased versus prior periods.
What is ADPT's long-term revenue growth rate?
Adaptive Biotechnologies Corporation's 5-year revenue CAGR of +23.0% reflects the sustained expansion pattern. Current YoY growth of +35.1% is above this long-term average.
How is ADPT's revenue distributed by segment?
ADPT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.